Myotec and Hybrid merge to form PsiOxus
This article was originally published in Scrip
Executive Summary
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.